Reports

At Medical Research Collaborative, the brunt of our time will be spent researching, debating, vetting, writing, editing, and then ultimately disseminating reports to our Data Partners, while continuously monitoring/updating our partners on the target companies covered, with any internal resources available thereafter allocated to the procurement of customized reports. Customized Reports are compiled by request and under contract with interested parties, and become the co-ownership of such parties. They may copy, share, print, and disseminate these reports at will. However, certain of our reports will also find their way into this section and become available for public purchase/download. 

Privacy

Client confidentiality is important to us; your identity and/or the identity of the firm you represent is kept confidential, and such information only accessible to executive management. Please see our Privacy Notice for more information.

Refund Policy

As the content of our research contained within each report is considered proprietary information, and the viewing of a report containing our research equivalent to using that report, we do not issue refunds; therefore, all sales are final.

Terms of Use

Please review our Terms of Use before purchase.


For more information, please see our FAQ section. We may also be contacted directly to answer any questions or to assist you with the process.



DISCLAIMER

The information contained in any and all research reports written, edited, and/or assembled by Medical Research Collaborative, LLC does not, and is not intended to, constitute legal or medical advice, and is for informational purposes only. In addition, we do not warrant or guarantee the success of any investment decision you make for yourself or on behalf of your firm in reliance upon the content of our research; we recommend securing the services of a registered investment advisor (which we are not) and performing your own independent investigations before acting on information that we publish.


Why it is Highly Improbable the Court Will Find Defendants' ANDA Labels as Inducing Infringement (Amarin v. DRL/Hikma)

Why it is Highly Improbable the Court Will Find Defendants' ANDA Labels as Inducing Infringement (Amarin v. DRL/Hikma)

Part I/II of MRC’s Critique of Amarin’s Assertions of Inducement and Non-Obviousness in its Proposed..

$299.00

What Can Be Inferred from the Summary Judgement Ruling [EXPANDED], and Recent Developments

What Can Be Inferred from the Summary Judgement Ruling [EXPANDED], and Recent Developments

Summary:Update on section 1.6 from our greater report, entitled "AMRN: Market Headwinds and Inherent..

$0.00

AMARIN V. DRL/HPU LEGAL ANALYSIS ON INDUCEMENT AND VASCEPA PRIOR ART

AMARIN V. DRL/HPU LEGAL ANALYSIS ON INDUCEMENT AND VASCEPA PRIOR ART

Summary:Legal analysis on inducement and prior art relevant to Amarin v. Dr Reddy's Labs/Hikma Pharm..

$0.00

AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP

AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP

AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP   Summary Since having ..

$0.00

Showing 1 to 4 of 4 (1 Pages)